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Abstract
Background Several smartphone applications (app) with an automated risk assessment claim to be able to detect skin
cancer at an early stage. Various studies that have evaluated these apps showed mainly poor performance. However, all
studies were done in patients and lesions were mainly selected by a specialist.
Objectives To investigate the performance of the automated risk assessment of an app by comparing its assessment
to that of a dermatologist in lesions selected by the participants.
Methods Participants of a National Skin Cancer Day were enrolled in a multicentre study. Skin lesions indicated by the
participants were analysed by the automated risk assessment of the app prior to blinded rating by the dermatologist.
The ratings of the automated risk assessment were compared to the assessment and diagnosis of the dermatologist.
Due to the setting of the Skin Cancer Day, lesions were not veriﬁed by histopathology.
Results We included 125 participants (199 lesions). The app was not able to analyse 90 cases (45%) of which nine
BCC, four atypical naevi and one lentigo maligna. Thirty lesions (67%) with a high and 21 with a medium risk (70%) rating
by the app were diagnosed as benign naevi or seborrhoeic keratoses. The interobserver agreement between the ratings
of the automated risk assessment and the dermatologist was poor (weighted kappa = 0.02; 95% CI 0.08-0.12;
P = 0.74).
Conclusions The rating of the automated risk assessment was poor. Further investigations about the diagnostic accu-
racy in real-life situations are needed to provide consumers with reliable information about this healthcare application.
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Introduction
The smartphone has become an integral part of our daily lives.
There are many smartphone applications (apps) on the consumer
market for the evaluation of moles, facilitating follow-up of
lesions, performing automated risk assessments (ARAs) or pro-
viding an e-consultation with a dermatologist.1 The SkinVision
app (SVA) (SkinVision, Amsterdam, The Netherlands) has been
found to be the most frequently downloaded app of this kind on
the Android store.1 Consumers can get lesions automatically
analysed and receive an instant rating as low, medium or high
risk. Lesions can be reviewed by a dermatologist. Various stud-
ies2–5 that have evaluated apps using automated analysis includ-
ing the SVA or similar apps showed mainly poor performance.
However, all studies2–6 so far were done in patients instead of in†These authors share senior authorship
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2019
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
DOI: 10.1111/jdv.15873 JEADV
the general population and only in one pilot study2 patients them-
selves were asked to indicate the lesions they were worried about.
In all other studies,3–6 the lesions were selected by a physician.
The aim of this study was to evaluate the performance of the
ARA of the SVA by investigating the interobserver agreement
between the dermatologist and the ARA in lesions indicated by
participants of the study.
Methods
Study design and participants
The National Skin Cancer Day in the Netherlands was an annu-
ally recurring campaign to raise awareness of skin cancer and
provide information on sun safety measures. It was mainly pro-
moted through a poster campaign and local press releases. Pos-
ters were distributed to general practitioners, dermatologists and
pharmacies. At the National Skin Cancer Day, participants could
consult a dermatologist for a free skin check-up and receive
medical advice at participating clinics. Participants were advised
to consult their general practitioner if further treatment or a
diagnostic procedure was necessary. Due to the legal aspects of
the campaign day, it was not possible to excise suspicious lesion
for histopathological investigation. At four academic hospitals in
the Netherlands (Leiden University Medical Center, Amsterdam,
Medical Center/VU University Medical Center, Maastricht
University Medical Center and Erasmus University Medical Cen-
ter, Rotterdam), participants of the National Skin Cancer Day,
from the age of 18 years, were asked to take part in this study.
After written informed consent, participants were asked to
point out a maximum of two lesions they were concerned about
and in which case they would have potentially used the app
themselves. A researcher entered the risk profile of the lesion
and imaged the lesions with an iPhone using the in-app auto-
matic camera which was facilitated by the SVA. The at that time
point available version of the app was used in all centres.
Between centres, different iPhone models were used, all of them
supporting the app and the instant rating (green, yellow, red)
was noted. Participants were blinded to the outcome of this pro-
cedure. A maximum of five attempts was made to capture the
lesion; if the attempts were unsuccessful, the lesion was tagged as
‘unable to perform analysis’. Afterwards, the same lesions were
rated and diagnosed by an expert dermatologist in skin cancer
(dermatologists working in skin cancer centres of the four afore-
mentioned academic referral hospitals with more than 5 years of
experience in skin cancer diagnosis, treatment and research in
skin cancer) who was blinded for the results previously acquired
by the SVA. Dermoscopy was used as a complementary diagnos-
tic tool. Benign lesions were rated as green; lesions like atypical
naevi, which should be followed up by the visitor, were rated as
yellow; and (pre)malignant lesions that needed physician’s con-
sultation were rated as red. Due to the setting of the Skin Cancer
Day, lesions were not verified by histopathology. At the Leiden
University Medical Center and the Maastricht University Medi-
cal Center, two dermatologists rated in consensus. The local
medical ethical committees approved the study.
Data were collected in Excel, and descriptive statistics were
performed in SPSS (IBM SPSS Statistics for Windows, version
24.0. Armonk, NY, U.S.A: IBM Corp). Weighted Kappa (Kw)
and 95% confidence intervals (CIs) were calculated to determine
SVA-dermatologist agreement. Kappa values were interpreted
based on the Landis and Koch guidelines.7 The chi-square test
was used to compare the characteristics of persons and lesions
that could or could not be analysed by the SVA. Median and
interquartile range (IQR) were measured for age. Statistical sig-
nificance was stated as P < 0.05.
Results
On 20 May 2017, about 3500 participants were seen in 83 der-
matological practices. A total of 297 participants were registered
at the four academic centres on the Dutch National Skin Cancer
Day. One hundred twenty-five participants (199 lesions) agreed
to take part in this study. Characteristics of participants and the
localization of lesions are detailed in Table 1. In 45% of the 199
lesions, the app was not able to take a picture for analysis. ARA
was green (low risk) in 31% of the lesions, yellow (moderate
risk) in 28% and red (high risk) in 41%, while the dermatologist
rating was green in 84%, yellow in 8% and red in 8% of the
lesions (Table 2a). Of the ARA red rating, 84% of the lesions
were rated as green by the dermatologist, 2% was rated as yellow
and 13% were rated as red. Of all green ARA, 79% were also
rated green by the dermatologist. In 21% of cases, the dermatol-
ogist reported a yellow or red rating. Of the lesions where the
app was unable to perform analysis, 81% were rated as green,
6% as yellow and 13% as red by the dermatologist (Table 2b).
The interobserver agreement between the ARA and the
Table 1 Characteristics of participants
Number of participants 125
Sex, n (%)
Male 31 (31)
Female 69 (69)
Total male and female 100 (100)
Missing 25
Age in years (median, IQR) 50 (40–62)
Number of participants with x lesions, n (%)
Participants with one lesion 51 (41)
Participants with two lesions 74 (59)
Total number of lesions, n 199
Location of lesion, n (%)
Head/neck 39 (20)
Trunk 101 (51)
Upper extremity 32 (16)
Lower extremity 27 (14)
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dermatologist was poor (weighted kappa = 0.02; 95% CI -0.08-
0.12; P = 0.74). Sixty-seven per cent of the lesions with a red rat-
ing and 70% with a yellow rating by the ARA were diagnosed as
a benign naevus or a seborrhoeic keratosis by the dermatologist.
Two lesions, which were diagnosed as basal cell carcinoma
(BCC) by the dermatologist, got either a green or yellow rating
by the ARA (Table 3a). In nine cases of BCC, four atypical naevi
and one lentigo maligna, the app was unable to perform the
analysis (Table 3b). Comparison between the characteristics of
patients and location per lesion that could or could not be ana-
lysed by the app only showed that in the head/neck area in a sig-
nificantly higher proportion of lesions, the app was unable to
perform the analysis (Table S1).
Discussion
This study showed a poor agreement of the rating of skin lesions
selected by participants of a skin cancer campaign day between
the ARA and the rating and the diagnosis of the dermatologist.
This is in line with the findings of previous studies2,3 testing the
same app on patients visiting a pigmented lesion clinic. The cur-
rent study differs from the previous ones in that in this study, a
large cohort of participants of a campaign day and not patients
were included in a multicentre trial. In the previous studies, the
group was preselected by including patients who already
intended to see a dermatologist. Nabil et al.2 suggested that their
outcome would even be stronger in the general population. They
argued2 that laypersons are not able to distinguish between
cancerous lesions and benign lookalikes such as a benign naevus
and seborrhoeic keratosis and that the app is not able to perform
well in unselected lesions, either. The current study group repre-
sents the general population better since the participants were
visitors of a campaign day and not patients. In accordance with
this fact, most lesions indicated as suspicious by the SVA (66%
of the red rating) were benign naevi and seborrhoeic keratoses.
In another study,8 only lesions suspicious for melanoma were
included after selection by a dermatologist. A sensitivity of 73%
and a specificity of 83% were found for melanoma. In this set-
ting, most benign lesions like banal naevi and seborrheic ker-
atoses had already been excluded. Thissen et al.9 validated a
modification on the SVA algorithm and found a sensitivity of
80% and a specificity of 78% for (pre)malignant lesions. Also in
this study,9 lesions were selected by a dermatologist and it is not
clear from the study design if specific lesions were selected for
the purpose of validation. Other studies3–5 which also included
malignant lesions testing the SVA or a similar anonymous app
showed a low accuracy of the app. Ngoo et al.3 who tested the
SVA and several other apps on both benign and malignant
lesions concluded that the agreement between the apps and the
Table 2 (a) ARA vs rating of the dermatologist; (b) ARA unable to
perform analysis vs rating of the dermatologist
(a) Rating dermatologist, n (%)† Total of
rating
ARA, n
Green Yellow Red
ARA Green 27 (79*) 5 (15**) 2 (6***) 34
Yellow 26 (87*) 3 (10**) 1 (3***) 30
Red 38 (84*) 1 (2**) 6 (13***) 45
Total rating dermatologist, n 91 9 9 109
(b) Rating dermatologist,
n (%)
Total,
n (%)
Green Yellow Red
ARA unable to perform analysis, n 73 (81) 5 (6) 12 (13) 90 (100)
†Percentage of the ARA that was given, respectively, a green*/yellow**/
red*** rating by the dermatologist.
ARA, automated risk assessment.
Benign lesions were rated as green; lesions like atypical naevi, which should
be followed up by the participant, were rated as yellow; and (pre)malignant
lesions that needed physician’s consultation were rated as red by the derma-
tologist.
Table 3 (a) Rating of the ARA vs diagnosis of the dermatologist; (b) ARA unable to perform analysis vs diagnosis of the dermatologist
(a) Diagnosis dermatologist, n (%) Total,
nBenign
naevus
Atypical
naevus
Seb.
keratosis
Actinic
keratosis
BCC M. Bowen Solar
lentigo
Dermatoﬁbroma Angioma Other
benign
Rating
ARA, n
Green 20 (59) 4 (12) 4 (12) 0 (0) 1 (3) 0 (0) 3 (9) 2 (6) 0 (0) 0 (0) 34
Yellow 19 (63) 2 (7) 2 (7) 0 (0) 1 (3) 0 (0) 3 (10) 2 (7) 1 (3) 0 (0) 30
Red 15 (33) 1 (2) 15 (33) 1 (2) 4 (9) 1 (2) 2 (4) 3 (7) 0 (0) 3 (7) 45
Total n 54 7 21 1 6 1 8 7 1 3 109
(b) Diagnosis dermatologist, n (%)† Total,
n (%)Benign
naevus
Atypical
naevus
Seb.
keratosis
Actinic
keratosis
BCC Solar
lentigo
Lentigo
Maligna
Dermatoﬁbroma Angioma Other
benign
ARA unable
to perform
analysis, n
35 (39) 4 (4) 14 (16) 8 (9) 9 (10) 7 (8) 1 (1) 3 (3) 3 (3) 6 (7) 90 (100)
†Percentage of the ARA rating that was given a speciﬁc diagnosis by the dermatologist.
Abbreviations: ARA, automated risk assessment; BCC, basal cell carcinoma.
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dermatologist was limited. Doraiay et al.5 also demonstrated a
very low diagnostic accuracy for a similar app and showed that
eight of the nine high-risk lesions were missed. Also, Wolf et al.4
who tested three apps with an automated rating found that 30%
or more of the melanomas were classified as unconcerning by
the apps. A recent review10 concluded that ‘existing automated
apps are unreliable’ and that certificates do not implicate good
performance.
What was furthermore remarkable in this study was the fact
that 45% of the lesions could not be analysed by the app. Investi-
gators in two earlier studies3,8 also had difficulties analysing sus-
picious skin lesions. They reported that they failed to analyse up
to 26% of the lesions and Ngoo et al.3 wondered how consumers
would respond. They3 also demonstrated that using the iOS plat-
form, which we used in our study, resulted in less failures than
using the android system. Among others, the lesions that could
not be analysed by the app in this study were nine basal cell car-
cinomas, one lentigo maligna and four atypical naevi. We do not
know if consumers would have initiated a medical consultation
in these cases. Furthermore, it might have been more problem-
atic to acquire adequate pictures in the head/neck area. We
found a significant higher proportion of lesions that could not
be analysed by the app in that anatomic area (Table S1).
The fact that most lesions were benign stresses our opinion
that the current study setting comes close to a real-life situation
where most lesions that will be tested by the consumer are
benign.
Our study has certain limitations. Histopathological assess-
ment was not carried out since it was a campaign day. Further-
more, the app was unable to make an assessment in a large
number of cases, even though all steps were taken to ensure opti-
mal imaging. Thus, this study could have underestimated the
capabilities of the app. Conversely, the aim of this study was to
test the app in a daily practice setting in which app failures are
inherently and unavoidably present.
Based on the results of this study, it is not possible to make
statements about SVA’s ability to detect melanoma. Only one
lentigo maligna was diagnosed by the dermatologists in our
study. The app was unable to perform an assessment on that
lesion. The strength of our study is the broad spectrum of partic-
ipants due to the multicentre setting at an open day. Moreover,
participants selected the lesions themselves and not the derma-
tologist. The option to get a review of the picture by an in-house
dermatologist which was just introduced at that point was not
investigated. At the moment of writing, pictures of lesions with a
red rating can be reviewed by a dermatologist for free. However,
a recent review article11 about teledermatology found a variable
diagnostic agreement of 51–85% with the reference standard
(histopathology for excised lesions and clinical diagnosis for
others) for the diagnosis of skin cancer. The conclusion of a
Cochrane review12 about teledermatology for the diagnosis of
skin cancer was that ‘. . .the evidence base to support its ability
to accurately diagnose lesions and to triage lesions from primary
to secondary care is lacking. . .’.
We did not investigate the question if the use of different
iPhone models might have influenced our results. However, the
rating provided by the app should be the same with different
phone models, since all of them supported the app.
Despite the fact that participants of the study were not
patients but visitors of the National Skin Cancer day, we still
cannot exclude selection bias. Most participants were female
(69%) with a median age of 50 from four geographical regions
in the Netherlands covering most of the population. We expect
that in real life, users of the app might be younger but also pre-
dominately female since women are more likely to perform skin
self-examination.13,14
Other applications of the app like the option to follow-up a
lesion and the possibility to send a picture to a dermatologist
while a patient is under follow-up were not investigated in this
study but might be of potential benefit.
With technology further evolving, new and updated versions
of apps, emerging deep learning algorithms and artificial intelli-
gence networks15–17 will inevitably come to play in skin cancer
care in the future. But before integrating them into daily prac-
tice, safety and efficacy need to be proven.
Our results highlight that caution is warranted before recom-
mending and using these applications in a real-life setting. A
European CE certification only means that a product has techni-
cally met EU health, safety and environmental requirements and
is based on self-certification (ce.europe.eu). For consumers, it is
important to know at a glance if there is reliable scientific sup-
port for the claims of an app.6 Therefore, regulations integrating
scientific research and validation in real-life situations are
urgently needed to provide consumers with reliable information.
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